Table 1 Representative TMEM16A inhibitors for cancer
From: TMEM16A as a potential treatment target for head and neck cancer
Name | Target | Cancer types | Reported year | References |
|---|---|---|---|---|
T16Ainh-A01 | NF-kB, EGFR signaling | Breast, HNSCC, Pancrea | 2014- | |
CaCCinh-A01 | ER-associated proteasomal degradation | HNSCC | 2014 | [91] |
Arctigenin | MAPK pathway | Lung adenocarcinoma | 2020 | [92] |
Dehydroandrographolide | Directly inhibit TMEM16A | Colorectal | 2015 | [93] |
Simvastatin | Mevalonate acid-dependent pathway | OSCC | 2021 | [94] |
Luteolin | PI3K/AKT, NF-kB, XIPA, p53 | Prostate | 2008- | |
Niclosamide | NOTCH signaling, NF-kB, Wnt/beta-Catenin signaling, IL-6-JAK1-STAT3 pathway, GSK-3, other | Leukemia, OSCC, Ovarian, Hepatocellular carcinoma | 2009- | |
Homoharrimgtonine | MiR-18a-3p-AKT-mTOR pathway | Lung, Breast, Leukemia | 2019- | |
Cepharanthine | Detailes unknown | Lung adenocarcinoma | 2021 | [112] |
Avermectin | Endogenous TMEM16A-mediated currents | Lung adenocarcinoma | 2020 | [113] |
Benzophenanthridine alkaloid | Endogenous TMEM16A currents | Lung adenocarcinoma | 2020 | [114] |
Theaflavin | Directly inhibit TMEM16A | Lung adenocarcinoma | 2021 | [115] |
Silibinin | Apoptosis, Cyclin D1 | Lung adenocarcinoma | 2021 | [116] |
Zafirlukast | Directly inhibit TMEM16A | Lung adenocarcinoma | 2022 | [117] |
Matrine | Directly inhibit TMEM16A and its currents | Lung adenocarcinoma | 2018 | [118] |
Nuciferine | Enhance anti-cancer effect of cisplatin | Lung adenocarcinoma | 2022 | [119] |
Ani9 | Directly inhibit TMEM16A | Malignant glioma | 2016 | [120] |